The medical community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 receptor that’s showing significant promise in clinical trials for addressing obesity. Unlike some current weight loss solutions, retatrutide appears to offer a significant substantial decrease in body size and benefit metabolic markers, pa